Sign in
Taking people in United StatesNo phase

Personalized Exercise Training for Transthyretin Cardiac Amyloidosis

Tests a personalized exercise program in older adults with transthyretin cardiac amyloidosis.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Exercise Training in Transthyretin Cardiac Amyloidosis
Status
Recruiting
People taking part
40 people, planned
Started
10 Jul 2024
Expected to end
30 Jun 2030
Type of study
Interventional
Treatments tested
  • Exercise Training
Record updated
18 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults with transthyretin cardiac amyloidosis and heart failure who can walk and are stable enough to join an exercise training program.

Age
60 to 90 years
Sex
All sexes can join
Disease stage
Transthyretin cardiac amyloidosis (ATTR-CM) confirmed by heart biopsy or a positive pyrophosphate (PYP) scan of Grade 2 or 3. Heart failure with past or current need of diuretics and N-terminal prohormone B-natriuretic peptide (BNP) of 450 pg/ml or more. Able to walk 4 meters and manage basic daily activities alone.
Earlier treatment
For part 2 of the study only: must be taking tafamidis.
Biomarker or test result
N-terminal prohormone B-natriuretic peptide (BNP) of 450 pg/ml or more. For part 2 only: peak VO2 below 80% of predicted.

Main reasons for not taking part

  • Recent acute heart attack, more than 70% blocked heart arteries, or severe aortic valve narrowing
  • Already doing formal heart exercise programs or regular moderate to vigorous exercise
  • Light chain amyloidosis, other non-ATTR amyloidosis, or nerve damage from a TTR gene change
  • Ventricular assist device, or any organ transplant
  • Advanced kidney disease (eGFR below 20 mL/min/1.73m2), or life expectancy under 1 year from another terminal illness

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Diagnosis and typing of ATTR-CM by endomyocardial biopsy or by Grade 2 or Grade 3 pyrophosphate (PYP) positivity (exception: nonamyloid control arm in aim 1); Diagnosis of heart failure, with prior or current need of diuretics and increased N-terminal prohormone B-natureitic peptide (BNP) (≥450 pg/ml); Peak VO2 <80% predicted, indicating impaired aerobic capacity (for aim 2 only); Taking tafamidis (for aim 2 only); Able to walk 4 meters (with or without the use of an assistive device) and independent with basic activities of daily living at the time of enrolment; Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention; Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

Who cannot take part

  • Acute myocardial infarction (Note: given that cardiac biomarkers such as troponin are frequently elevated in ATTR-CM patients, the diagnosis of acute myocardial infarction should be based on clinical diagnosis, not biomarkers alone); >70% obstructive coronary artery disease; Severe aortic valve stenosis; Already actively participating in formal, facility-based cardiac exercise; Already engaging in regular moderate to vigorous exercise conditioning defined as > 30 minutes per day, ≥ twice per week consistently during the previous 6 weeks; Ventricular assist device; Light chain amyloidosis or other form of non-ATTR amyloidosis; Advanced chronic kidney disease defined as estimated glomerular filtration rate <20 mL/min/1.73m2; Any organ transplantation; Terminal illness other than HF with life expectancy < 1 year; Pacemaker or implantable cardioverter-defibrillato (ICD) with heart rate limits < expected heart rates for exercise and unable to be reprogrammed; Neuropathy due to transthyretin (TTR) mutation; Impairment from stroke, injury or other medical disorder that precludes participation in the intervention; Abnormal cardiopulmonary exercise testing (CPET) finding that requires further investigation and management; Dementia that precludes ability to participate in exercise and follow study protocols; High risk for non-adherence as determined by screening evaluation; Inability or unwillingness to comply with the study requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 60 and 90 years old?

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Sarah Cuddy, MDTaking people

About the trial

What the trial wants to find out

Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.

The group in the trial

  • Intervention armTreatment being tested

    Treatment: Exercise Training

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis
Plain-language title
Personalized Exercise Training for Transthyretin Cardiac AmyloidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05797857, who can take part
Record updated
18 March 2025